# CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

> **NCT04480788** · PHASE1 · UNKNOWN · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- T Lymphoblastic Leukemia/Lymphoma
- Extramedullary NK-T-cell Lymphoma, Nasal Type
- Peripheral T-cell Lymphoma, Nonspecific
- Angioimmunoblastic T-cell Lymphoma
- Enteropathy-Associated T-Cell Lymphoma
- Anaplastic Large Cell Lymphoma, ALK-negative
- T-cell Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** T cell injection targeting CD7 chimeric antigen receptor

## Key facts

- **NCT ID:** NCT04480788
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-24
- **Primary completion:** 2022-08-01
- **Final completion:** 2022-08-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2021-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480788, "CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04480788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*